Rodos BioTarget GmbH
Rodos BioTaget GmbH: Fresh Capital for Nanomedicine Development against Chronic Inflammatory Autoimmune Diseases
DGAP-News: Rodos BioTaget GmbH
/ Key word(s): Financing
Hannover / Potsdam, January 16, 2019. Rodos Biotarget GmbH implemented financing measures over EUR 2.3 million. All of the company’s current investors have participated in the accompanying capital increase. The majority of capital was raised from ILB – the business promotion bank in the federal state of Brandenburg – and their ERDF-Subsidy “ProFIT” (EUR 1.8 million). At the company’s location in Science Park Potsdam, Rodos Biotarget develops a therapeutic concept based on its own nanocarrier platform TargoSphere(R) to intervene with fundamental cellular disease mechanisms of chronic inflammatory autoimmune diseases (CIADs). In their advanced stages, CIAD-related diseases such as psoriasis, multiple sclerosis, rheumatoid arthritis, or inflammatory bowel diseases can sometimes be treated very successfully with biologicals. The nanomedicine approach pursued by Rodos Biotarget differs from such humoral or cellular therapies already in the market or in pharmaceutical development in that suitable therapeutic agents are entered into antigen-presenting cells via the targeted nanocarriers. These immune cells are located at the onset of the individual disease cascades. In CIADs, they are dysregulated and thus instruct certain T-helper cells to release disease-specific signal substances (e.g., cytokines, chemokines). The inflammatory process builds up steadily and results in the development of the symptoms typical of the respective disease. Exactly this pathological vicious circle should be interrupted by the approach of Rodos Biotarget. Ideally, this concept could be applied to a whole range of CIADs with high medical need. Rodos Biotarget GmbH Online Presence: http://www.biotargeting.eu Contact Rodos Biotarget GmbH Rodos Biotarget GmbH
16.01.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |